REPROCELL supports Silo Pharma with successful human tissue testing in Rheumatoid Arthritis study
On 16 October 2023, Silo Pharma announced positive data for the effects of SPU-21 in inflamed human synovial tissue to inhibit the progression of rheumatoid arthritis (RA). Preclinical data from...
REPROCELL Announces License Agreement with Gameto for the Advancement of its Program to Improve Assisted Fertility using iPSCs
Gameto plans to use the iPSC line to advance its program, Fertilo, designed to improve IVF and egg freezing. YOKOHAMA, Japan — REPROCELL Inc. today announced that it has entered into an agreement to...
Bioserve Biotechnologies Partners with BioMavericks Ltd. to Expand Presence in the UK market
[Hyderabad, India, 27 September 2023] – Bioserve Biotechnologies (India) Private Limited, a leader in molecular biology products, is teaming up with BioMavericks Ltd., a UK-based company. This...
As REPROCELL emerges from the first quarter of 2023-24, we are thrilled to present a snapshot of the activities and achievements that have set the stage for a productive year. From the launch of our...
COLCHESTER, VERMONT and YOKOHAMA, Japan, 11 July 2023 – Vernal Biosciences, a leader in mRNA and LNP manufacturing, and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company,...
Joint Research Agreement with Keio University on Tumor-Infiltrating Lymphocyte Therapy for Cervical Cancer
We are pleased to announce that REPROCELL has entered into a joint research agreement with Keio University regarding “transfer of technology for the production of Tumor Infiltrating Lymphocytes (TIL)...
01 June 2023, Glasgow, UK and Daresbury, UK: REPROCELL today announces the launch of a new commercial service, Pharmacology-AI. The launch follows the completion of one of the first EXCELERATE...
Yokohama Japan, 25 May 2023: We are pleased to announce the results of the Phase II clinical trial in Japan (protocol number: RS-01) of our regenerative medicine product Stemchymal® (allogeneic...
Yokohama Japan, 23 May 2023: REPROCELL will now offer CDMO services to manufacture Advanced Therapies Medicinal Products (ATMPs) generated from mesenchymal stem cells (MSC) through a partnership with...
End of Q4 update from REPROCELL (2022-23)
Did you know that REPROCELL is celebrating its 20th anniversary this year? If you missed the commemorative letter from our CEO we have included a link below - plus everything else we’ve been up to...
Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial
REPROCELL USA, a CRO, has been awarded a contract to provide support for Lantern Pharma’s Phase 2 clinical trial entitled “A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers with...
Celebrating the 20th Anniversary of REPROCELL: A letter from our CEO Chikafumi Yokoyama
On February 26, 2023, REPROCELL celebrated its 20th anniversary. I would like to express our sincere gratitude to our customers who use our products and services, our shareholders who have invested...
End of Q3 update from REPROCELL (2022-23)
The year might be coming to a close, but we’re not winding down at REPROCELL. The final months of 2022 have brought new collaborations, partnerships, and successes to enrich your stem cell and drug...
Silo Pharma, Inc. has announced its plans to initiate a pilot study of its novel joint homing peptides targeting rheumatoid arthritis (RA), designated as SPU-21, in human synovial tissue surrounding...
REPROCELL invests in Histocell, S.L. a Spain-based CDMO
Yokohama Japan, 23 November 2022: REPROCELL Inc. decided to invest in Histocell S.L. to strengthen its clinical induced pluripotent stem cell (iPSC) service offerings. Histocell is a CDMO based in...
Building economic resilience and unleashing productivity through digital innovation
UK enterprises are facing a number of disruptive forces that necessitate transformation at pace – macro-economic challenges, socio-political challenges, and the focus on our own resilience....
REPROCELL Inc. and JTB Corp. form a business alliance to provide Personal iPS Service to domestic and overseas customers
Yokohama, Japan, 13 October 2022: REPROCELL Inc. and JTB Corp. will begin marketing "Personal iPS" (REPROCELL's iPSC storage and production service) overseas through the Japan Medical & Health...
Yokohama Japan, 5 October 2022: REPROCELL Inc. has agreed to join the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program to make accessible REPROCELL’s unique...
REPROCELL and BioBridge Global sign Memorandum of Understanding to accelerate global manufacturing services using clinical iPSCs
YOKOHAMA, Japan: REPROCELL Inc. and San Antonio, Texas-based BioBridge Global have signed a Memorandum of Understanding to enhance their strategic collaborative relationship. The agreement will...
End of Q2 update from REPROCELL (2022-23)
We're halfway through the financial year and there are only three months left in 2022. Time is racing but REPROCELL has managed to pack in a lot since our last update, including three conferences and...